Model-based Dose Optimization Framework for Bedaquiline, Pretomanid, and Linezolid for the Treatment of Drug-Resistant Tuberculosis.
Krina MehtaTingjie GuoPiet H Van der GraafJ G Coen van HasseltPublished in: British journal of clinical pharmacology (2023)
The model-based simulations suggested that comparable efficacy can be achieved using alternative bedaquiline and linezolid dosing, which may improve safety and adherence in drug-resistant tuberculosis patients. The framework can be utilized to evaluate treatment optimization approaches, including dosing regimen and duration of treatment predictions to eradicate both replicating- and non-replicating bacteria from lung and lesions.
Keyphrases
- drug resistant
- multidrug resistant
- acinetobacter baumannii
- end stage renal disease
- mycobacterium tuberculosis
- chronic kidney disease
- newly diagnosed
- emergency department
- adipose tissue
- peritoneal dialysis
- hiv aids
- pulmonary tuberculosis
- insulin resistance
- weight loss
- hiv infected
- patient reported
- human immunodeficiency virus